Novo Nordisk presents results from studies at World Diabetes Congress

1 December 2015

Global diabetes care giant Novo Nordisk (NOV: N) has today presented the results of four diabetes studies at the World Diabetes Congress in Vancouver this week.

The first study evaluated the relative efficacy of Victoza (liraglutide) compared to sodium-glucose co-transporter-2 (SGLT-2) inhibitors in people with type 2 diabetes uncontrolled on metformin alone or in combination with sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitors or thiazolidinedione.

The results revealed that treatment with Victoza provides greater HbA 1c reduction and an improved likelihood of reaching glycemic targets compared to SGLT-2 inhibitors, namely canagliflozin, dapagliflozin and empagliflozin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK